176 related articles for article (PubMed ID: 36195293)
1. Structural or functional defects of PTEN in urothelial cells lacking P53 drive basal/squamous-subtype muscle-invasive bladder cancer.
He F; Zhang F; Liao Y; Tang MS; Wu XR
Cancer Lett; 2022 Dec; 550():215924. PubMed ID: 36195293
[TBL] [Abstract][Full Text] [Related]
2. PI3K/AKT pathway activation in bladder carcinogenesis.
Calderaro J; Rebouissou S; de Koning L; Masmoudi A; Hérault A; Dubois T; Maille P; Soyeux P; Sibony M; de la Taille A; Vordos D; Lebret T; Radvanyi F; Allory Y
Int J Cancer; 2014 Apr; 134(8):1776-84. PubMed ID: 24122582
[TBL] [Abstract][Full Text] [Related]
3. Trp53 Mutation in Keratin 5 (Krt5)-Expressing Basal Cells Facilitates the Development of Basal Squamous-Like Invasive Bladder Cancer in the Chemical Carcinogenesis of Mouse Bladder.
Masuda N; Murakami K; Kita Y; Hamada A; Kamada M; Teramoto Y; Sakatani T; Matsumoto K; Sano T; Saito R; Okuno Y; Ogawa O; Kobayashi T
Am J Pathol; 2020 Aug; 190(8):1752-1762. PubMed ID: 32339497
[TBL] [Abstract][Full Text] [Related]
4. Tumorigenesis of basal muscle invasive bladder cancer was mediated by PTEN protein degradation resulting from SNHG1 upregulation.
Li T; Huang M; Sun N; Hua X; Chen R; Xie Q; Huang S; Du M; Zhao Y; Lin Q; Xu J; Han X; Zhao Y; Tian Z; Zhang Y; Chen W; Shen X; Huang C
J Exp Clin Cancer Res; 2024 Feb; 43(1):50. PubMed ID: 38365726
[TBL] [Abstract][Full Text] [Related]
5. Hypermethylation of FOXA1 and allelic loss of PTEN drive squamous differentiation and promote heterogeneity in bladder cancer.
Osei-Amponsa V; Buckwalter JM; Shuman L; Zheng Z; Yamashita H; Walter V; Wildermuth T; Ellis-Mohl J; Liu C; Warrick JI; Shantz LM; Feehan RP; Al-Ahmadie H; Mendelsohn C; Raman JD; Kaestner KH; Wu XR; DeGraff DJ
Oncogene; 2020 Feb; 39(6):1302-1317. PubMed ID: 31636388
[TBL] [Abstract][Full Text] [Related]
6. Alterations of mTOR and PTEN protein expression in schistosomal squamous cell carcinoma and urothelial carcinoma.
Makboul R; Refaiy A; Abdelkawi IF; Hameed DA; Elderwy AA; Shalaby MM; Merseburger AS; Hussein MR
Pathol Res Pract; 2016 May; 212(5):385-92. PubMed ID: 26916953
[TBL] [Abstract][Full Text] [Related]
7. Oncogenic HRAS Activates Epithelial-to-Mesenchymal Transition and Confers Stemness to p53-Deficient Urothelial Cells to Drive Muscle Invasion of Basal Subtype Carcinomas.
He F; Melamed J; Tang MS; Huang C; Wu XR
Cancer Res; 2015 May; 75(10):2017-28. PubMed ID: 25795707
[TBL] [Abstract][Full Text] [Related]
8. Inactivation of p53 and Pten promotes invasive bladder cancer.
Puzio-Kuter AM; Castillo-Martin M; Kinkade CW; Wang X; Shen TH; Matos T; Shen MM; Cordon-Cardo C; Abate-Shen C
Genes Dev; 2009 Mar; 23(6):675-80. PubMed ID: 19261747
[TBL] [Abstract][Full Text] [Related]
9. Targeted Pten deletion plus p53-R270H mutation in mouse mammary epithelium induces aggressive claudin-low and basal-like breast cancer.
Wang S; Liu JC; Kim D; Datti A; Zacksenhaus E
Breast Cancer Res; 2016 Jan; 18(1):9. PubMed ID: 26781438
[TBL] [Abstract][Full Text] [Related]
10. Olig1/2-Expressing Intermediate Lineage Progenitors Are Predisposed to PTEN/p53-Loss-Induced Gliomagenesis and Harbor Specific Therapeutic Vulnerabilities.
Verma R; Chen X; Xin D; Luo Z; Ogurek S; Xin M; Rao R; Berry K; Lu QR
Cancer Res; 2023 Mar; 83(6):890-905. PubMed ID: 36634201
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical based molecular subtypes of muscle-invasive bladder cancer: association with HER2 and EGFR alterations, neoadjuvant chemotherapy response and survival.
Helal DS; Darwish SA; Awad RA; Ali DA; El-Guindy DM
Diagn Pathol; 2023 Feb; 18(1):11. PubMed ID: 36737799
[TBL] [Abstract][Full Text] [Related]
12. BTG2 is a tumor suppressor gene upregulated by p53 and PTEN in human bladder carcinoma cells.
Tsui KH; Chiang KC; Lin YH; Chang KS; Feng TH; Juang HH
Cancer Med; 2018 Jan; 7(1):184-195. PubMed ID: 29239139
[TBL] [Abstract][Full Text] [Related]
13. Radiation/paclitaxel treatment of p53-abnormal non-small cell lung cancer xenograft tumor and associated mechanism.
Li G; Zhao J; Peng X; Liang J; Deng X; Chen Y
Cancer Biother Radiopharm; 2012 May; 27(4):227-33. PubMed ID: 22489661
[TBL] [Abstract][Full Text] [Related]
14. The evolution of bladder cancer genomics: What have we learned and how can we use it?
Audenet F; Attalla K; Sfakianos JP
Urol Oncol; 2018 Jul; 36(7):313-320. PubMed ID: 29573965
[TBL] [Abstract][Full Text] [Related]
15. Activation of p53-dependent growth suppression in human cells by mutations in PTEN or PIK3CA.
Kim JS; Lee C; Bonifant CL; Ressom H; Waldman T
Mol Cell Biol; 2007 Jan; 27(2):662-77. PubMed ID: 17060456
[TBL] [Abstract][Full Text] [Related]
16. Genomic characterization of non-schistosomiasis-related squamous cell carcinoma of the urinary bladder: A retrospective exploratory study.
Al-Ezzi EM; Veitch ZW; Salah SH; Van der Kwast TH; Stockley TL; Selvarajah S; Zhang T; Sridhar SS; Sacher AG; Fallah-Rad N; Kulkarni GS; Zlotta AR; Finelli A; Hansen AR
PLoS One; 2021; 16(12):e0259272. PubMed ID: 34851968
[TBL] [Abstract][Full Text] [Related]
17. Hyperplasia and carcinomas in Pten-deficient mice and reduced PTEN protein in human bladder cancer patients.
Tsuruta H; Kishimoto H; Sasaki T; Horie Y; Natsui M; Shibata Y; Hamada K; Yajima N; Kawahara K; Sasaki M; Tsuchiya N; Enomoto K; Mak TW; Nakano T; Habuchi T; Suzuki A
Cancer Res; 2006 Sep; 66(17):8389-96. PubMed ID: 16951148
[TBL] [Abstract][Full Text] [Related]
18. PI3K/mTOR inhibitor PF-04691502 antitumor activity is enhanced with induction of wild-type TP53 in human xenograft and murine knockout models of head and neck cancer.
Herzog A; Bian Y; Vander Broek R; Hall B; Coupar J; Cheng H; Sowers AL; Cook JD; Mitchell JB; Chen Z; Kulkarni AB; Van Waes C
Clin Cancer Res; 2013 Jul; 19(14):3808-19. PubMed ID: 23640975
[TBL] [Abstract][Full Text] [Related]
19. Loss of the urothelial differentiation marker FOXA1 is associated with high grade, late stage bladder cancer and increased tumor proliferation.
DeGraff DJ; Clark PE; Cates JM; Yamashita H; Robinson VL; Yu X; Smolkin ME; Chang SS; Cookson MS; Herrick MK; Shariat SF; Steinberg GD; Frierson HF; Wu XR; Theodorescu D; Matusik RJ
PLoS One; 2012; 7(5):e36669. PubMed ID: 22590586
[TBL] [Abstract][Full Text] [Related]
20. Alterations of EGFR, p53 and PTEN that mimic changes found in basal-like breast cancer promote transformation of human mammary epithelial cells.
Pires MM; Hopkins BD; Saal LH; Parsons RE
Cancer Biol Ther; 2013 Mar; 14(3):246-53. PubMed ID: 23291982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]